BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 27595677)

  • 1. Independent and incremental prognostic value of novel cardiac biomarkers in chronic hemodialysis patients.
    Obokata M; Sunaga H; Ishida H; Ito K; Ogawa T; Ando Y; Kurabayashi M; Negishi K
    Am Heart J; 2016 Sep; 179():29-41. PubMed ID: 27595677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective Validation of a Screening Biomarker Approach Combining Amino-Terminal Pro-Brain Natriuretic Peptide With Galectin-3 Predicts Death and Cardiovascular Events in Asymptomatic Hemodialysis Patients.
    Voroneanu L; Siriopol D; Apetrii M; Hogas S; Onofriescu M; Nistor I; Kanbay M; Dumea R; Cusai S; Cianga P; Constantinescu D; Covic A
    Angiology; 2018 May; 69(5):449-455. PubMed ID: 28974104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Superior prognostic value of soluble suppression of tumorigenicity 2 for the short-term mortality of maintenance hemodialysis patients compared with NT-proBNP: a prospective cohort study.
    Wang Z; Chen Z; Yu H; Ma X; Zhang C; Qu B; Zhang W; Chen X
    Ren Fail; 2020 Nov; 42(1):523-530. PubMed ID: 32460670
    [No Abstract]   [Full Text] [Related]  

  • 4. N-terminal pro brain natriuretic peptide predicts mortality in patients with end-stage renal disease in hemodialysis.
    Madsen LH; Ladefoged S; Corell P; Schou M; Hildebrandt PR; Atar D
    Kidney Int; 2007 Mar; 71(6):548-54. PubMed ID: 17299526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3.
    Bayes-Genis A; de Antonio M; Vila J; Peñafiel J; Galán A; Barallat J; Zamora E; Urrutia A; Lupón J
    J Am Coll Cardiol; 2014 Jan; 63(2):158-66. PubMed ID: 24076531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. sST2 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity Troponin T.
    Emdin M; Aimo A; Vergaro G; Bayes-Genis A; Lupón J; Latini R; Meessen J; Anand IS; Cohn JN; Gravning J; Gullestad L; Broch K; Ueland T; Nymo SH; Brunner-La Rocca HP; de Boer RA; Gaggin HK; Ripoli A; Passino C; Januzzi JL
    J Am Coll Cardiol; 2018 Nov; 72(19):2309-2320. PubMed ID: 30384887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease.
    Bibbins-Domingo K; Gupta R; Na B; Wu AH; Schiller NB; Whooley MA
    JAMA; 2007 Jan; 297(2):169-76. PubMed ID: 17213400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased Soluble Suppression of Tumorigenicity 2 Level Predicts All-Cause and Cardiovascular Mortality in Maintenance Hemodialysis Patients: A Prospective Cohort Study.
    Zhang Z; Shen B; Cao X; Liu Z; Chen X; Nie Y; Yu J; Zou J; Ding X
    Blood Purif; 2017; 43(1-3):37-45. PubMed ID: 27875808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ST2 elevation in heart failure, predictive of a high early mortality.
    Dalal JJ; Digrajkar A; Das B; Bansal M; Toomu A; Maisel AS
    Indian Heart J; 2018; 70(6):822-827. PubMed ID: 30580851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ST2 as a novel prognostic marker in end-stage renal disease patients on hemodiafiltration.
    Homsak E; Ekart R
    Clin Chim Acta; 2018 Feb; 477():105-112. PubMed ID: 29221927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-terminal-pro-B-type-natriuretic peptide associated with 2-year mortality from both cardiovascular and non-cardiovascular origins in prevalent chronic hemodialysis patients.
    Kawagoe C; Sato Y; Toida T; Nakagawa H; Yamashita Y; Fukuda A; Iwatsubo S; Fujimoto S
    Ren Fail; 2018 Nov; 40(1):127-134. PubMed ID: 29457529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined use of high-sensitivity ST2 and NT-proBNP for predicting major adverse cardiovascular events in coronary heart failure.
    Bai J; Han L; Liu H
    Ann Palliat Med; 2020 Jul; 9(4):1976-1989. PubMed ID: 32762223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T.
    Dispenzieri A; Gertz MA; Saenger A; Kumar SK; Lacy MQ; Buadi FK; Dingli D; Leung N; Zeldenrust S; Hayman SR; Kapoor P; Grogan M; Hwa L; Russell SJ; Go RS; Rajkumar SV; Kyle RA; Jaffe A
    Am J Hematol; 2015 Jun; 90(6):524-8. PubMed ID: 25753178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic value of the plasma N-terminal pro-brain natriuretic peptide level on all-cause death and major cardiovascular events in a community-based population.
    Zhu Q; Xiao W; Bai Y; Ye P; Luo L; Gao P; Wu H; Bai J
    Clin Interv Aging; 2016; 11():245-53. PubMed ID: 27013868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive Ability of Novel Cardiac Biomarkers ST2, Galectin-3, and NT-ProBNP Before Cardiac Surgery.
    Polineni S; Parker DM; Alam SS; Thiessen-Philbrook H; McArthur E; DiScipio AW; Malenka DJ; Parikh CR; Garg AX; Brown JR
    J Am Heart Assoc; 2018 Jul; 7(14):. PubMed ID: 29982227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of multiple biomarkers for mortality prediction in patients with acute heart failure of ischemic and nonischemic etiology.
    Zhang M; Meng Q; Qi X; Han Q; Qi X; Wang F; Du B
    Biomark Med; 2018 Nov; 12(11):1207-1217. PubMed ID: 30499308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-terminal pro brain natriuretic peptide predicts both all-cause and cardiovascular disease mortality in Japanese hemodialysis patients.
    Satoh A; Doi S; Naito T; Nakashima A; Masaki T
    Clin Exp Nephrol; 2021 Oct; 25(10):1142-1150. PubMed ID: 34106372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble ST2 for Risk Stratification and the Prediction of Mortality in Patients Undergoing Transcatheter Aortic Valve Implantation.
    Stundl A; Lünstedt NS; Courtz F; Freitag-Wolf S; Frey N; Holdenrieder S; Zur B; Grube E; Nickenig G; Werner N; Frank D; Sinning JM
    Am J Cardiol; 2017 Sep; 120(6):986-993. PubMed ID: 28739033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The usefulness of sST2 and galectin-3 as novel biomarkers for better risk stratification in hypertrophic cardiomyopathy.
    Gawor M; Śpiewak M; Janas J; Kożuch K; Wróbel A; Mazurkiewicz Ł; Baranowski R; Marczak M; Grzybowski J
    Kardiol Pol; 2017; 75(10):997-1004. PubMed ID: 28612913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myocardial fibrosis combined with NT-proBNP improves the accuracy of survival prediction in ADHF patients.
    Yao Y; Feng L; Sun Y; Wang S; Sun J; Hu B
    BMC Cardiovasc Disord; 2021 May; 21(1):264. PubMed ID: 34049488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.